Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study-Reference-Cited by-同舟云学术

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

Published:2017-11-14 Issue:2 Volume:4 Page:475-488
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Tahir Hasan^ORCID,Deodhar Atul,Genovese Mark,Takeuchi Tsutomu,Aelion Jacob,Van den Bosch Filip,Haemmerle Sibylle,Richards Hanno B.

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s40744-017-0086-y.pdf

Reference23 articles.

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.

3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.

4. Rituximab: Highlights of prescribing information. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf (cited 12 July 2017).

5. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol. 2001;167(10):6015–20.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis;Journal of Biomedical Informatics;2024-06

2. Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?;Life;2024-05-31

3. From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?;Expert Opinion on Investigational Drugs;2024-05-09

4. Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain;Current Neuropharmacology;2024-02

5. Rheumatoid arthritis;The Rose and Mackay Textbook of Autoimmune Diseases;2024